DaxibotulinumtoxinA

Phase 3Small molecule

RRevance Therapeutics, Inc.

DaxibotulinumtoxinA is one of 37 small molecule programs targeting Migraine. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MigraineActive, not recruiting

BlepharospasmRecruiting

MigrainePreclinical

Active, not recruiting

BlepharospasmPhase 3

Recruiting

Competition

Competitive Landscape

105 competitors in Migraine

#DrugCompanyPhaseTrials

Zonegran

AAzurity Pharmaceuticals

Phase 3

3 2

Avicel

SSanthera Pharmaceuticals

Phase 3

2 3

Magnesium

SSpherium Biomed

Phase 3

3 4

Flunarizine

AAspartes Pharmaceuticals, Inc.

Phase 3

9 5

BAT7104

Teva

Phase 3

1 6

DaxibotulinumtoxinA

RRevance Therapeutics, Inc.

Phase 3

1 7

Tizanidine Hydrochloride

EElan Pharmaceuticals

Phase 3

1 8

Bayer Aspirin

Bayer

Preclinical

2 9

Cymbalta

Jazz Pharmaceuticals

Preclinical

1 10

Adempas

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Blepharospasm

NCT06195241

Clinical

Trials by Indication[1]

Cervical Dystonia1 trial

Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

Completed·RRevance Therapeutics, Inc.·Phase 2·NCT02706795·37 enrolled

Treatment1 trial

DaxibotulinimtoxinA for Treatment of Platysmal Neck Bands

Completed·MMain Line Center for Laser Surgery·Phase 4·NCT06225492·20 enrolled

Migraine1 trial

An Open Label, Study of DaxibotulinumtoxinA for Migraine Prevention

Active, not recruiting·KKi Health Partners. LLC··NCT06154070·10 enrolled

Blepharospasm1 trial

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

Recruiting·MMontefiore Medical Center·Phase 4·NCT06195241·40 enrolled

Spasmodic Dysphonia1 trial

DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT05158166·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for DaxibotulinumtoxinA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DaxibotulinumtoxinA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DaxibotulinumtoxinA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Revance Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRevance Therapeutics, Inc.

DaxibotulinumtoxinA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Cervical Dystonia1 trial

Treatment1 trial

Migraine1 trial

Blepharospasm1 trial

Spasmodic Dysphonia1 trial

References

Drug Info

Quick Facts

Related News